NCT00610883已完成2 期
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Complete Remission
研究概览
简要总结
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
- Induction ends on day 19
- Consolidation ends on day 38 or 42
- Maintenance may include up to 6 cycles
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-Hodgkin's Lymphoma stages III, IV, IVA with
- •T cell lymphomas, any primary site irrespective of LDH level
- •large cell lymphomas, any primary site irrespective of LDH level
- •B cell lymphomas, any primary site with initial LDH of less than 500
排除标准
- •B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
研究组 & 干预措施
1 - LSA4
Experimental
干预措施: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU (Drug)
结局指标
主要结局
Complete Remission
时间窗: 330 Days
The number of patients who achieved a complete remission as a result of treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's LymphomaLymphoma, Non-HodgkinNCT00044551Bayer29
招募中
Unknown
Increasing the survival of children with blood cancer in India using a standard treatment approach.CTRI/2023/12/060828Cancer Institute
已完成
不适用
Treatment of advanced, relapsed chronic lymphocytic leukemia (CLL) with fludarabine, miroxantrone and cyclophosphamide combination therapy with or without granulocyte colony stimulating factor (G-CSF)Relapsed B-cell chronic lymphocytic leukemia (B-CLL)Lymphoid leukaemiaCancerISRCTN31486124German CLL Study Group (GCLLSG) (Germany)165
Unknown
2 期
Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in ChildrenChildAcute Lymphoblastic LeukemiaNCT02339350The Korean Society of Pediatric Hematology Oncology110
已完成
2 期
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell LymphomasBurkitt LymphomaLymphoma, Large-Cell, DiffuseLymphoma, Small Noncleaved-CellNCT00001237National Cancer Institute (NCI)120